Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
- Published In:
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 34(12), 2213-2219 (2019)
- Authors:
- Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming-Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
- Database ID:
- RPEP-04308
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04308APA
Leder, Benjamin Z; Zapalowski, Carol; Hu, Ming-Yi; Hattersley, Gary; Lane, Nancy E; Singer, Andrea J; Dore, Robin K. (2019). Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 34(12), 2213-2219. https://doi.org/10.1002/jbmr.3848
MLA
Leder, Benjamin Z, et al. "Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.." Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019. https://doi.org/10.1002/jbmr.3848
RethinkPeptides
RethinkPeptides Research Database. "Fracture and Bone Mineral Density Response by Baseline Risk ..." RPEP-04308. Retrieved from https://rethinkpeptides.com/research/leder-2019-fracture-and-bone-mineral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.